Related Experiment Video
Updated: Jan 10, 2026
Gastric Mucosa Quantitative Polymerase Chain Reaction Analysis for Detecting Helicobacter pylori and Antibiotic Resistance
Published on: March 7, 2025
Antimicrobial Resistance Patterns of Clinical Helicobacter pylori Isolates From Gastric Cancer Patients
Yupei Zhang1,2, Kai Liu3,4, Xiaona Song5
1Center of Infectious Diseases, West China Hospital of Sichuan University, Chengdu, China.
Background:
The increasing antibiotic resistance of Helicobacter pylori poses challenges in selecting effective eradication therapies for patients with gastric cancer. This study aimed to assess the antibiotic resistance patterns of clinical H. pylori strains isolated from gastric cancer patients, to guide H. pylori eradication strategies for those with residual gastric mucosa after gastrectomy.
Methods:
This study enrolled 115 consecutive patients with gastric cancer who had a positive 13C urea breath test, all of whom were scheduled for gastric resection at West China Hospital of Sichuan University. Gastric mucosa samples were collected for pathological examination, H. pylori culture, and susceptibility testing using E-test and disk diffusion methods.
Results:
From 115 specimens, 86 H. pylori strains were cultured (74.8% culture rate). Of the 86 patients (59 males, 27 females; median age 59, range 34-79) with successful H. pylori isolation, histopathology revealed 37 intestinal-type, 27 diffuse-type, 9 mixed-type, and 13 unclassified gastric cancers. Sixty-one patients underwent distal gastrectomy, and 25 had radical total gastrectomy. Notably, 12 patients were diagnosed at ≤45 years, including 9 females, all with signet ring cell carcinoma. Antibiotic resistance rates were rifampicin (RIF) (69.8%), metronidazole (MTZ) (75.6%), clarithromycin (CLR) (41.9%), levofloxacin (LEV) (32.6%), amoxicillin (AML) (2.3%), tetracycline (TET) (1.2%), and furazolidone (FZD) (0%).
Conclusions:
H. pylori isolates from gastric cancer patients exhibited high resistance to RIF, MTZ, CLR, and LEV, but negligible resistance to AML, FZD, and TET. Given the compromised health status and need for concurrent therapies in these patients, AML- and/or minocycline-based regimens may represent a practical and effective treatment option for H. pylori eradication in gastric cancer patients with residual gastric mucosa after distal gastrectomy, to reduce the risk of metachronous gastric cancer.
Related Concept Videos
01:16Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy
01:28Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
01:23Gastritis III: Clinical Manifestations and Management
Clinical manifestations of acute gastritis
The patient with acute gastritis may have a rapid onset of symptoms, such as epigastric pain or discomfort, dyspepsia, anorexia, hiccups, or nausea and vomiting, which can last from a few hours to a few days. Erosive or hemorrhagic gastritis may cause bleeding, which may manifest as blood in vomit or as...
02:56Treatment Resistant Cancers
01:30Peptic Ulcer Disease I: Introduction
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...
01:28Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists